Dement Neurocogn Disord.  2018 Sep;17(3):110-119. 10.12779/dnd.2018.17.3.110.

¹⁸F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia

Affiliations
  • 1Department of Neurology, Inha University School of Medicine, Incheon, Korea.
  • 2Neuroscience Research Institute, Gachon University, Incheon, Korea.
  • 3Department of Neuroscience, Gachon University College of Medicine, Incheon, Korea.
  • 4Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 5Department of Neurology, Seoul Medical Center, Seoul, Korea.
  • 6Department of Neurology, Gachon University Gil Medical Center, Incheon, Korea. ynoh@gachon.ac.kr
  • 7Tohoku Medical and Pharmaceutical University, Sendai, Japan.
  • 8Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • 9Department of Health Science and Technology, GAIHST, Gachon University, Incheon, Korea.

Abstract

BACKGROUND AND PURPOSE
To analyze 18F-THK5351 positron emission tomography (PET) scans of patients with clinically diagnosed nonfluent/agrammatic variant primary progressive aphasia (navPPA).
METHODS
Thirty-one participants, including those with Alzheimer's disease (AD, n=13), navPPA (n=3), and those with normal control (NC, n=15) who completed 3 Tesla magnetic resonance imaging, 18F-THK5351 PET scans, and detailed neuropsychological tests, were included. Voxel-based and region of interest (ROI)-based analyses were performed to evaluate retention of 18F-THK5351 in navPPA patients.
RESULTS
In ROI-based analysis, patients with navPPA had higher levels of THK retention in the Broca's area, bilateral inferior frontal lobes, bilateral precentral gyri, and bilateral basal ganglia. Patients with navPPA showed higher levels of THK retention in bilateral frontal lobes (mainly left side) compared than NC in voxel-wise analysis.
CONCLUSIONS
In our study, THK retention in navPPA patients was mainly distributed at the frontal region which was well correlated with functional-radiological distribution of navPPA. Our results suggest that tau PET imaging could be a supportive tool for diagnosis of navPPA in combination with a clinical history.

Keyword

Primary Progressive Nonfluent Aphasia; tau Protein; Neurofibrillary Tangles; Positron Emission Tomography

MeSH Terms

Alzheimer Disease
Aphasia, Primary Progressive*
Basal Ganglia
Broca Area
Diagnosis
Frontal Lobe
Humans
Magnetic Resonance Imaging
Neurofibrillary Tangles
Neuropsychological Tests
Positron-Emission Tomography
Primary Progressive Nonfluent Aphasia
tau Proteins
tau Proteins

Figure

  • Fig. 1 18F-THK5351 PET and MRI (T1-MPRAGE) scans of navPPA patients. PET: positron emission tomography, MRI: magnetic resonance imaging, MPRAGE: magnetization prepared rapid gradient echo, navPPA: nonfluent/agrammatic variant primary progressive aphasia.

  • Fig. 2 Statistical parametric mapping analysis of THK SUVR images after PVC. Colored areas represent brain regions corresponding to increased THK retention from voxel-wise statistical analyses in those with navPPA (A) and AD (B) compared to NC (p<0.001, uncorrected for multiple comparisons after adjusting for age, gender, and years of education, a cluster >100). SUVR: standardized uptake value ratio, PVC: partial volume correction, navPPA: nonfluent/agrammatic variant primary progressive aphasia, AD: Alzheimer's disease, NC: normal control, T: T value.


Reference

1. Mesulam MM. Primary progressive aphasia--a language-based dementia. N Engl J Med. 2003; 349:1535–1542.
Article
2. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004; 55:335–346.
Article
3. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006; 129:1385–1398.
Article
4. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol. 2004; 56:399–406.
Article
5. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain. 2005; 128:1996–2005.
Article
6. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006; 59:952–962.
Article
7. Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006; 59:156–165.
Article
8. Harris JM, Gall C, Thompson JC, Richardson AM, Neary D, du Plessis D, et al. Classification and pathology of primary progressive aphasia. Neurology. 2013; 81:1832–1839.
Article
9. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol. 2010; 6:88–97.
Article
10. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015; 14:114–124.
Article
11. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016; 57:208–214.
Article
12. Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, et al. Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med. 2018; 59:671–674.
Article
13. Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017; 9:25.
Article
14. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011; 76:1006–1014.
Article
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 1984; 34:939–944.
Article
16. Kang Y, Jahng S, Na DL. Seoul Neuropsychological Screening Battery. 2nd ed. Seoul: Human Brain Research & Consulting Co.;2012.
17. Borroni B, Agosti C, Premi E, Cerini C, Cosseddu M, Paghera B, et al. The FTLD-modified Clinical Dementia Rating scale is a reliable tool for defining disease severity in frontotemporal lobar degeneration: evidence from a brain SPECT study. Eur J Neurol. 2010; 17:703–707.
Article
18. Kim EJ, Park KW, Lee JH, Choi S, Jeong JH, Yoon SJ, et al. Clinical and neuropsychological characteristics of a nationwide hospital-based registry of frontotemporal dementia patients in Korea: a CREDOS-FTD study. Dement Geriatr Cogn Dis Extra. 2014; 4:242–251.
Article
19. Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008; 131:2957–2968.
Article
20. Lee JH, Kim SH, Kim GH, Seo SW, Park HK, Oh SJ, et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology. 2011; 77:18–25.
Article
21. Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, et al. Seoul neuropsychological screening battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010; 25:1071–1076.
Article
22. Kim H, Na DL. Normative data on the Korean version of the Western Aphasia Battery. J Clin Exp Neuropsychol. 2004; 26:1011–1020.
Article
23. Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014; 55:1623–1628.
Article
24. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998; 39:904–911.
25. Rousset OG, Collins DL, Rahmim A, Wong DF. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med. 2008; 49:1097–1106.
Article
26. Seelaar H, Kamphorst W, Rosso SM, Azmani A, Masdjedi R, de Koning I, et al. Distinct genetic forms of frontotemporal dementia. Neurology. 2008; 71:1220–1226.
Article
27. Mesulam M, Wicklund A, Johnson N, Rogalski E, Léger GC, Rademaker A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol. 2008; 63:709–719.
Article
28. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006; 66:41–48.
Article
29. Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology. 2016; 87:2309–2316.
Article
30. Vettermann F, Brendel M, Danek A, Levin J, Bartenstein P, Okamura N, et al. [18F] THK-5351 PET in patients with clinically diagnosed progressive supranuclear palsy. J Nucl Med. 2016; 57:457.
31. Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, et al. Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2017; 24:130–136.
Article
32. Gorno-Tempini ML, Ogar JM, Brambati SM, Wang P, Jeong JH, Rankin KP, et al. Anatomical correlates of early mutism in progressive nonfluent aphasia. Neurology. 2006; 67:1849–1851.
Article
33. Kremen SA, Mendez MF, Tsai PH, Teng E. Extrapyramidal signs in the primary progressive aphasias. Am J Alzheimers Dis Other Demen. 2011; 26:72–77.
Article
34. Ferrari J, Pontello N, Martinez-Cuitiño M, Borovinsky G, Gleichgerrcht E, Torralva T, et al. Extrapyramidal signs across variants of primary progressive aphasias. Mov Disord. 2014; 29 Suppl 1:598.
35. Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011; 58:60–68.
Article
Full Text Links
  • DND
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr